Please assess the completion status of the following clinical trial:

Trial Title: Shingles Prevention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 60 years of age and older.~* History of Chickenpox.~* Have given written informed consent prior to enrollment.~* History of varicella or long-term (greater than or equal to 30 years) residence in the continental USA.~Exclusion Criteria:~* No history of shingles, no current history of immune suppression (e.g. malignancy or neoplastic disease, corticosteroid therapy).~* No immunosuppression resulting from disease (e.g., malignancy; HIV infection), corticosteroids (except intermittent topical or inhaled corticosteroid \[greater than 800 mcg/day beclomethasone dipropionate or equivalent\]), or other immunosuppressive/cytotoxic therapy (cancer chemotherapy or organ transplantation).~* No active neoplastic disease (except local skin cancer or other malignancies \[e.g., prostate cancer\] that are stable in the absence of immunosuppressive/cytotoxic therapy).~* No prior Herpes Zoster.~* No prior receipt of varicella vaccine.~* No allergic sensitivity to neomycin.~* No history of anaphylactoid reaction to gelatin.~* No significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 5 years).~* Not ambulatory (must not be bed-ridden or homebound).~* No receipt of immune globulin or any other blood product within 3 months before or planned during the 3-5 year study period.~* No receipt of any other immunizations within one month before study vaccination (2 weeks in the case of inactivated influenza vaccines or other non-replicating immunization products \[e.g., dT, pneumococcal vaccine, hepatitis A vaccine, hepatitis B vaccine\]), or scheduled within 6 weeks after study vaccination.~* Not currently receiving antiviral therapy.~* No other condition (e.g., extensive psoriasis, chronic pain syndrome, cognitive impairment, severe hearing loss) that, in the opinion of the investigator, might interfere with the evaluations required by the study.~* No intercurrent illness (e.g., urinary tract infection, influenza) that might interfere with the interpretation of the study.~* No females who are pre-menopausal.~* No subjects unlikely to adhere to protocol follow-up.~* No subjects involved in a conflicting (vaccine or investigational drug) clinical trial.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): varicella-zoster vaccine
- Arm 2 (Type: PLACEBO_COMPARATOR): vaccine placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).